Literature DB >> 15136787

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Napoleone Ferrara1, Kenneth J Hillan, Hans-Peter Gerber, William Novotny.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15136787     DOI： 10.1038/nrd1381

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  770 in total

1.  Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.

Authors:  Igor A Astsaturov; Neal J Meropol; R Katherine Alpaugh; Barbara A Burtness; Jonathan D Cheng; Sue McLaughlin; André Rogatko; Zhiheng Xu; James C Watson; Louis M Weiner; Steven J Cohen
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

2.  Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

Authors:  Hedy L Kindler; Theodore G Karrison; David R Gandara; Charles Lu; Lee M Krug; James P Stevenson; Pasi A Jänne; David I Quinn; Marianna N Koczywas; Julie R Brahmer; Kathy S Albain; David A Taber; Samuel G Armato; Nicholas J Vogelzang; Helen X Chen; Walter M Stadler; Everett E Vokes
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 3.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

Review 4.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

Review 5.  Antiangiogenic therapies for glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew D Norden
Journal:  CNS Oncol       Date:  2014

6.  Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.

Authors:  Gerald S Falchook; Jennifer J Wheler; Aung Naing; Sarina A Piha-Paul; Siqing Fu; Apostolia M Tsimberidou; David S Hong; Filip Janku; Ralph Zinner; Yunfang Jiang; Mei Huang; Quan Lin; Kristin Parkhurst; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2014-11-04       Impact factor: 3.850

Review 7.  Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Authors:  S A Kono; L E Heasley; R C Doebele; D R Camidge
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

Review 8.  New approaches in angiogenic targeting for colorectal cancer.

Authors:  Aleix Prat; Esther Casado; Javier Cortés
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

9.  Curcumin inhibits human non-small cell lung cancer xenografts by targeting STAT3 pathway.

Authors:  Xiaofang Xu; Yuping Zhu
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 10.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.